ARS-COV-2 lethality rate in Colombia: years 2020 y 2021

Letalidad por SARS-CoV-2 en Colombia años 2020 y 2021

Article Sidebar


PDF (Español (España)) FLIP HTML (Español (España)) EPUB (Español (España)) AUDIO (mp3) (Español (España))

How to Cite
Díaz Pinzón, J. E. (2022). ARS-COV-2 lethality rate in Colombia: years 2020 y 2021. Journal of Medicine and Surgery Repertoire, 31, 52–56. https://doi.org/10.31260/RepertMedCir.01217372.1341
Published: Jun 14, 2022
Doi
https://doi.org/10.31260/RepertMedCir.01217372.1341
Issue
Vol. 31 (2022): Suplemento COVID-19
Section
Research Article
License terms

   

Main Article Content

Jorge Enrique Díaz Pinzón
Secretaría de Educación de Soacha
https://orcid.org/0000-0002-8870-7769

Abstract

Introduction: This pandemic poses the need to understand how to survive infections and why treatment may be heterogenous. Objective: to review the COVID-19 case fatality rate in Colombia between March 6, 2020 and December 31, 2021. Methodology: a cross-sectional study. Data was obtained from the Ministry of Health and Social Protection website based on the COVID – 19 vaccination plan. Results: COVID-19 case fatality rates were established by months in 2020 and 2021 in Colombia. It was observed that for the abovementioned period, the month with the highest case fatality rate was February 2021 with 3.69% and the lowest was December 2021 with 1.61%. Conclusion: the records of lethality and mortality rates enable monitoring the pandemic but are biased due to delays in confirming SAR-CoV2 infection and delays in reporting.

Keywords:

Downloads

Download data is not yet available.

Article Details

Author Biography

Jorge Enrique Díaz Pinzón, Secretaría de Educación de Soacha

Ingeniero. Magister en Gestión de la Tecnología Educativa, Especialista en Administración de la Informática Educativa. Docente de matemáticas e Investigador. Secretaría de Educación de Soacha, Cundinamarca, Colombia.

 

References

Wang J, Yin-Chi C, Niu R, Wong E, Van Wyk M. Modeling the Impact of Vaccination on COVID-19 and its Delta Variant. Research Square. 2021. https://doi.org/10.21203/rs.3.rs-1171015/v1 DOI: https://doi.org/10.21203/rs.3.rs-1171015/v1

Belongia EA, Osterholm MT. COVID-19 and flu, a perfect storm. Science. 2020;368(6496):1163. doi: 10.1126/science.abd2220 DOI: https://doi.org/10.1126/science.abd2220

Wigginton NS. Cunningham RM, Katz RH, Lidstrom M, Moler KA, Wirtz D, Zuber MT. Moving academic research forward during COVID-19. Science. 2020;368(6496):1190-1192. doi: 10.1126/science.abc5599 DOI: https://doi.org/10.1126/science.abc5599

Jeong H, Rogers J, Xu S. Continuous on-body sensing for the COVID-19 pandemic: Gaps and opportunities. Sci Adv. 2020;6(36):eabd4794. doi: 10.1126/sciadv.abd4794 DOI: https://doi.org/10.1126/sciadv.abd4794

Singer BD. COVID-19 and the next influenza season. Sci Adv. 2020;6(31):eabd0086. doi: 10.1126/sciadv.abd0086 DOI: https://doi.org/10.1126/sciadv.abd0086

Ayres JS. Surviving COVID-19: A disease tolerance perspective. Sci Adv. 2020;6(18):eabc1518. doi: 10.1126/sciadv.abc1518 DOI: https://doi.org/10.1126/sciadv.abc1518

Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412 DOI: https://doi.org/10.1126/science.367.6485.1412

Ayres JS. The Biology of Physiological Health. Cell. 2020;181(2):250-269. https://doi.org/10.1016/j.cell.2020.03.036 DOI: https://doi.org/10.1016/j.cell.2020.03.036

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS -CoV-2. Science. 2020;369(6499):77-81. doi: 10.1126/science.abc1932 DOI: https://doi.org/10.1126/science.abc1932

World Health Organization. Coronavirus Disease (COVID-19) Dashboard [Internet]. 2021 [Consultado 25 de julio de 2021]. Disponible en: https://covid19.who.int/

Moreno-Altamirano A, López-Moreno S, Corcho-Berdugo A. Principales medidas en epidemiología [Internet]. 2017 [Citado 25 de julio de 2020]. Disponible en: https://www.scielosp.org/article/spm/2000.v42n4/337-348/es/ DOI: https://doi.org/10.1590/S0036-36342000000400009

Quintana-Salgado L. Medidas de frecuencia en epidemiología [Internet]. 2015 [Citado 25 de julio de 2020]. Disponible en: https://es.slideshare.net/lualberts20/medidas-de-frecuencia-en-epidemiologa-2015

Díaz Pinzón JE. Descripción estadística del COVID- 19 según el grupo etario en Colombia. Repert Med Cir. 2020;29(Núm. Supl. 1):79–85. https://doi.org/10.31260/RepertMedCir.01217372.1098 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1098

Díaz Pinzón JE. Continuidad con los procesos pedagógicos de los estudiantes durante la pandemia ocasionada por el COVID-19. Repert Med Cir. 2020;29(Núm. Supl. 1):108–112. https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1128

Díaz Pinzón, J. E. (2020). Positividad y proporción para muestras por COVID-19 en Colombia. 2020;29(Núm. Supl. 1):127–130. https://doi.org/10.31260/RepertMedCir.01217372.1134 DOI: https://doi.org/10.31260/RepertMedCir.01217372.1134

Instituto Nacional de Salud. Coronavirus (COVID-19) en Colombia [Internet]. 2022 (Consultado Ene 2022). Disponible en: https://www.ins.gov.co/Paginas/Inicio.aspx

Ward S, Lindsley A, Courter J, Assa A. Clinical testing for COVID-19. J Allergy Clin Inmunol. 2020;146(1):23–34. https://doi.org/10.1016/j.jaci.2020.05.012 DOI: https://doi.org/10.1016/j.jaci.2020.05.012

Bravo L, Grillo-Ardila E. Análisis de mortalidad por COVID-19 en Colombia: Medidas de ocurrencia. Univ Salud. 2020;22(3):292-298. https://doi.org/10.22267/rus.202203.202 DOI: https://doi.org/10.22267/rus.202203.202

Citado por